| Combination of | |
|---|---|
| Disufenton sodium | Antioxidant |
| Acetylcysteine | Antioxidant |
| Clinical data | |
| Other names | Disufenton/N-acetylcysteine; HPN-07/NAC; NHPN-1010; NXY-059/NAC |
| Drug class |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Unknown |
| Excretion | Unknown |
Disufenton/acetylcysteine (also known as HPN-07/NAC, NHPN-1010, or NXY-059/NAC) is an investigational combination therapy consisting of the nitrone free-radical trap disufenton sodium and the antioxidant N-acetylcysteine (NAC). It has been studied in preclinical research for noise-induced sensorineural hearing loss, tinnitus, cochlear synaptopathy, and traumatic brain injury, although as of 2024 there is no reported clinical development for any indication. [1]
Disufenton/acetylcysteine is described as acting through free-radical inhibition and oxygen-radical scavenging, processes relevant to oxidative stress injury in auditory and neural tissues. [2]
Oxidative stress and neuroinflammation contribute to noise induced cochlear injury, ribbon-synapse loss, and tinnitus-related neuronal hyperactivity. [3]
Animal models have suggested that the combination may reduce behavioral correlates of tinnitus following noise trauma, likely via protection of inner-hair-cell synapses and reduction of neural hyperactivity. [4]